A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer

This is a first-in-human study testing CBA-1205, a new antibody drug that targets a protein called DLK1 found on certain cancer cells. It is being tested in adults with advanced solid tumors (including liver cancer and melanoma) and in children with cancer who have no remaining standard treatment options. **You may be eligible if...** - You are an adult with advanced solid tumors, liver cancer (hepatocellular carcinoma), or melanoma that has not responded to standard treatments - You are a Japanese child (ages 2–19) with cancer that has not responded to standard treatments - You are in relatively good physical condition (able to perform basic daily activities) - Your blood counts and kidney function are within acceptable ranges **You may NOT be eligible if...** - You have had major surgery, chemotherapy, or radiation within the past 2–4 weeks - You have uncontrolled side effects from prior cancer treatment (Grade 2 or higher) - You are pregnant or breastfeeding - You have active infections or other serious medical conditions Talk to your doctor to see if this trial is right for you.